The soap operas we’ve grown to love over the last few decades have never shied away from outlandish storylines, unbelievable ...

Love is in the air, and what better way to celebrate Valentine's Day than with a lineup of classic TV episodes filled with ...

The Phase IIb study evaluated the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis (MASH) analyses to send its stock up about 100%.

After 96 weeks, 39% of patients offered a 50-mg dose of efruxifermin showed a clinically meaningful reduction in liver fibrosis, or scarring, without other symptoms of MASH getting worse ...

Shares of Akero ascended by 115% in early Monday trading upon the news. MASH-associated cirrhosis patients “face a poor prognosis,” Catriona Yale, chief development officer at Akero, said on an ...